Drug tolerance to target therapy in melanoma revealed at single cell level: What next?

Domenico Liguoro, Luigi Fattore, Rita Mancini, Gennaro Ciliberto

Research output: Contribution to journalReview articlepeer-review

Abstract

Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This phenomenon is commonly fueled by intrinsic or acquired mechanisms. In this mini-review, focusing on BRAF-mutated melanoma as prototypical example, we analyze how recent studies that make use of single cell analysis identify the involvement of distinct transcriptional trajectories as the common thread at the basis of drug tolerance. The identification of these transcriptional trajectories provide a mechanistic basis for the development of both intrinsic and acquired drug resistance. These studies also suggest that hitting these transcriptional trajectories through personalized adaptive treatments can delay or abrogate the onset of drug resistance.

Original languageEnglish
Article number188440
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1874
Issue number2
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Drug resistance
  • Melanoma
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Drug tolerance to target therapy in melanoma revealed at single cell level: What next?'. Together they form a unique fingerprint.

Cite this